Skip to main content

Table 1 Studies deriving risk indices for solid organ pancreas transplantation

From: Risk indices predicting graft use, graft and patient survival in solid pancreas transplantation: a systematic review

Study, year (transplant type) Risk index (intended use) Cohort size, source (study dates) Outcome Variables entered Final model variables Model type Discrimination Calibration*
Axelrod D 2010 (All) [3] Pancreas donor risk index (pre-transplant to inform donor organ acceptance) 9401 pancreas recipients from SRTR registry, USA (2000–2006) 1-year pancreas graft survival (All) Donor: age, BMI, gender, race, height, cause of death, DCD and creatinine
Recipient: age, BMI, gender, race, PRA, previous PVD, primary payment type, albumin, previous transplant
Other: transplant centre, duct management, degree of HLA matching, preservation time and transplant year
Donor age, BMI, gender, black or Asian race, cause of death, creatinine, height, DCD status, CIT, PAK transplant with a CVA donor Cox regression model (n = 1) 0.67 Observed: 1351
Predicted: NI
Dorsey SG 1997 (All) [13] Logistic regression model and a neural network model (pre-transplant) 160 pancreas recipients from single centre, USA (1991–1996) 3-month pancreas survival (All) Donor: age
Recipient: age, blood transfusions, smoking and alcohol history, diabetes duration, RRT pre-transplant
Other: sex or weight mismatch, having a PAK/PTA transplant, use of nonlocal organ procurement centre, HLA-DR mismatch
All variables used Logistic regression model (n = 1) 0.78
Model sensitivity 35.7%
Observed: 23
Predicted: NI
H–L p = 0.74
R2 = 0.24
       Neural network model (n = 1) Correctly predicted 92.5% of cases
Model sensitivity 68%
Model specificity 96%
Observed: 23
Predicted: NI
R2 = 0.71
Finger EB 2013 (All) [12] Composite risk model (pre-transplant) 1115 pancreas recipients from single centre, USA (1998–2011) 3-month death-censored pancreas failure (All) Donor: age, gender, race, cause of death, drug/alcohol abuse, pancreatitis history, BMI, DCD status, terminal creatinine, amylase, time to death from admission, CIT, PDRI
Recipient: age, gender, BMI, re-transplantation, previous vascular disease, pre-transplant dialysis, smoking status
Other: PRA, number of HLA mismatches, type of exocrine drainage
Donor age, BMI, CIT, terminal creatinine, presence of bladder drainage Cox regression model (n = 1) 0.6 (≥ 1 risk factors)
0.59 (≥ 2 risk factors)
0.52 (≥ 3 risk factors)
Observed: 10.2% graft failure
Predicted: 12.8% (≥ 1 risk factor)
26.7% (≥ 2 risk factors)
42.9% (≥ 3 risk factors)
Grochowiecki T 2014 (SPK) [32] Logistic regression model 112 pancreas recipients from single centre, Poland (1988–2010) Patient survival (timepoint unclear) (SPK) Donor: age, gender, cause of death
Recipient: age, gender, diabetes duration, RRT type and duration
Other: type and time of pancreas/kidney anastomosis, type of enteric anastomosis, total ischaemia time, immunosuppression type
Donor age, duration of pancreas anastomosis (vascular), dialysis duration Logistic regression model (n = 1) 0.8 Observed: 14
Predicted: NI
Kasiske BL 2013 (All) [33] 12 Cox regression models (to model survival outcomes by transplant type for viability of prospective pooling of transplant types for future survival analysis) 6078 pancreas recipients from SRTR registry, USA (2003–2010) 1-year SPK graft survival Donor: age, BMI, deceased donor, PVD at listing, cause of death
Recipient: age, BMI, gender, race, duration of dialysis, age of diabetes diagnosis, whether working or hospitalized at time of transplant, previous PVD, PRA, HLA mismatch
Other: CIT, retransplantation, if pre-emptive kidney transplant
Donor: age, BMI, gender, cause of death, PDRI
Recipient: age, BMI, gender, race, preservation method, whether working or hospitalized at time of transplant, pre-emptive kidney transplant, diabetes duration, diabetes type, peripheral vascular disease history, terminal eGFR and eGFR on discharge, PRA, previous pancreas transplant
Other: CIT
Cox regression models (n = 12) 0.63 (0.60–0.67) H–L p = 0.44
    1-year PAK graft survival     0.63 (0.58–0.69) H–L p = 0.32
    1-year PTA graft survival     0.68 (0.61–0.75) H–L p = 0.6
    1-year SPK patient survival     0.62 (0.57–0.69) H–L p = 0.77
    1-year PAK patient survival     0.75 (0.62–0.88) H–L p = 0.83
    1-year PTA patient survival     0.78 (0.58–0.98) H–L p = 0.74
    3-year SPK graft survival     0.59 (0.56–0.62) H–L p = 0.38
    3-year PAK graft survival     0.6 (0.56–0.64) H–L p = 0.81
    3-year PTA graft survival     0.66 (0.61–0.71) H–L p = 0.68
    3-year SPK patient survival     0.64 (0.6–0.68) H–L p = 0.92
    3-year PAK patient survival     0.68 (0.59–0.77) H–L p = 0.71
    3-year PTA patient survival     0.76 (0.66–0.86) H–L p = 0.24
Smigielska K 2018 (All) [11] Logistic regression model (pre-transplant) 408 pancreas recipients, multicentre, Poland (1998–2015) 1-year pancreas graft survival (All) No clear specification of all baseline variables (only donor variables considered) Donor age, BMI Logistic regression model (n = 1) 0.61 (0.56–0.66) Observed: 268
Predicted: NI
Sousa M 2014 (SPK) [35] Two Cox regression models (pre-transplant) 292 pancreas recipients, single centre, Brazil (2000–2010) 3-month pancreas survival Donor: age, BMI, gender, creatinine, sodium, amylase, norepinephrine, cause of death
Recipient: age, BMI, duration of dialysis, duration of diabetes, need for dialysis, gender, cyclosporine, use of induction therapy, type of preservation fluid
Other: CIT of pancreas and kidney, sequence of transplantation (pancreas or kidney first), type of duodenal anastomosis and venous drainage
Donor age, recipient BMI, use of induction therapy, iliac venous drainage, pancreas implantation first Cox regression model (n = 2) 0.72 (0.65–0.78) Observed: 56
Predicted: NI
    1-year patient survival Donor: age, BMI, gender, creatinine, sodium, amylase, norepinephrine, cause of death
Recipient: age, BMI, duration of dialysis, duration of diabetes, need for dialysis, gender, cyclosporine, use of induction therapy, type of preservation fluid
Other: CIT of pancreas and kidney, sequence of transplantation (pancreas or kidney first), type of duodenal anastomosis and venous drainage
Recipient BMI, use of induction therapy Cox regression model (n = 2) 0.67 (0.59–0.75) Observed: 48
Predicted: NI
Vinkers MT 2008 (pancreas donors) [4] Pre-procurement pancreas suitability score (pre-transplant to inform donor organ acceptance) 2175 pancreas donors from Eurotransplant database (2002–2005) Donor pancreas acceptance for transplant Donor: age, BMI, gender, cause of death, cardiac arrest duration, duration of ICU stay, sodium, amylase, lipase, use of vasopressors Donor age, BMI, duration of ICU stay, duration of cardiac arrest, sodium, amylase/lipase, use of inotropes Logistic regression model (n = 1) NI Observed: 45.3% of grafts declined
Predicted: 42.8% risk of P-PASS ≥ 17 and graft declined
O/E ratio: 1.06
  1. All graft survival are unadjusted unless specified
  2. *Observed and expected outcomes are for 1-year pancreas survival for PDRI and donor pancreas acceptance for P-PASS (as they are both the outcomes PDRI and P-PASS were derived against respectively) unless otherwise specified
  3. BMI body mass index, CCD Clinical Consensus Document, CIT cold ischaemia time, CVA cerebrovascular accident, DCD donor after cardiac death, eGFR estimated glomerular filtration rate, H–L Hosmer–Lemeshow test, HLA human leukocyte antigen, ICU intensive care unit, NI no information, O/E observed and predicted (expected) ratio, p p value, PAK pancreas after kidney transplant, PDRI pancreas donor risk index, P-PASS pre-procurement pancreas suitability score, PRA panel-reactive antibody, PTA pancreas transplant alone, PVD peripheral vascular disease, R2 coefficient of determination, SPK simultaneous pancreas-kidney transplant, SRTR Scientific Registry of Transplant Recipients, UK United Kingdom, USA United States of America